Full Press Release Details
NEW YORK, NY--(Marketwire - February 10, 2009) - Daxor Corporation (AMEX: DXR), a medical
instrumentation and biotechnology company, today announced the publication
of the scientific article, "The availability of circulating blood volume
values alters fluid management in critically ill surgical patients" in this
month's issue of The American Journal of Surgery.
In this two phase study, clinical investigators conducted a pilot study of
eight (8) patients to determine if utilizing a measured blood volume from
Daxor's Blood Volume Analyzer BVA-100 would alter their fluid management in
critically ill surgical patients. Upon discovering that fluid management
would change 50% of the time, forty (40) additional patients were
subsequently enrolled to participate in a pre- and post-interventional
In the prospective study clinicians began treating patients based on
current surrogate measures. Following their initial treatment, the blood
volume analysis data was revealed to clinicians and any change in treatment
due to the blood volume information was recorded. 86 blood volume
measurements revealed a change in 31 cases, which represented a 36% change
in treatment. No negative response occurred due to the change in treatment
with a 39% improved clinical response to the treatment alteration.
The standard of care for the infusion of fluid and blood products within
the critical care unit is currently not guided by a direct measurement of
blood volume; rather clinicians rely on surrogate tests along with signs
and symptoms, which have been shown to be relatively inaccurate. Previous
studies utilizing Daxor's BVA-100 in the critical care arena have been
retrospective observational studies. This study represents the first
prospective study which demonstrated that a measured blood volume
contributes to improving fluid management in the critically ill surgical
patient. Other studies which demonstrate specific clinical outcomes of a
measured blood volume in the critical care arena are ongoing, the results
of which are expected to be reported soon. The result of this study and
other studies which demonstrate improvements in care are important to the
adoption of the Blood Volume Analyzer becoming a standard of care.
This article can be found in the February 2009 issue, Volume 197, Number 2,
pages 232-237 of the American Journal of Surgery (AJS). AJS is a
peer-reviewed journal designed for the general surgeon who performs
abdominal, cancer, vascular, head and neck, breast, colorectal, and other
Daxor Corporation manufactures and markets the BVA-100, a semi-automated
Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex,
Daxor's single use diagnostic kit. For more information regarding Daxor
Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website
Contact Information: Contact Information:
Chief Operating Officer